Ziac
Ventolin
Depakote
Tagamet

Salmeterol

ROFERON-A, 30 RONDEC DROPS, 32 RONDEC SYRUP, 32 RONDEC-DM SYRUP, 33 ropinirole, 21 rosiglitazone, 24 rosiglitazone metformin, 24 ROWASA, 28 ROXICODONE, 15 ROZEREM, 22 RYTHMOL, 18 SAIZEN, 26 salicylic acid 17%, 36 salicylic acid 17% collodion, 36 saliva substitute spray, 28 SALIVART, 28 salmeterol xinafoate, 33 salsalate, 15 SANDOSTATIN, 27 SANDOSTATIN LAR, 27 saquinavir mesylate, 17 sargramostim, 30 selegiline tabs, 21 selenium sulfide shampoo 1%, 35 selenium sulfide shampoo 2.5%, 35 SELSUN, 35 SELSUN BLUE, 35 senna, 28 senna docusate sodium, 28 SENOKOT, 28 SENOKOT-S, 28 SEPTRA, 18 SERAX, 20 SEREVENT, 33 SEROQUEL, 22 SEROSTIM, 26 sertraline, 21 SILVADENE, 35 silver sulfadiazine, 35 simethicone, 29 simvastatin, 19 SINEMET, 21 SINEMET CR, 21 SINGULAIR, 34 sitagliptin phosphate, 23 sodium chloride, 37 sodium chloride soln, 34 sodium hyaluronate, 23 sodium oxybate, 23 sodium phosphate sodium biphosphate, 28 sodium phosphates, 28 SOLIA, 24 SOMA, 23 somatropin, 26 sotalol, 18 SPIRIVA, 32 spironolactone, 19 spironolactone hydrochlorothiazide, 19 SPRINTEC, 25 stavudine, 17 STUART PRENATAL, 31 sucralfate, 29.

Fluticasone and salmeterol

In one year-long study of children with mild to moderate asthma, salmeterol was not as effective as the corticosteroid beclomethasone, but it did reduce asthma symptoms without retarding growth. Click here to subscribe home drug prices search a advair diskus select word size: advair diskus generic for advair diskus country : india brand advair diskus country : uk list of drugs in a 5 asa advair diskus alphagan p o amantadine hcl astelin 1% nasal spray atacand hctz side effects side affect of generic for advair fluticasone-salmeterol ; generic advair diskus is a bronchodilator and corticosteroid combination fluticasone-salmeterol ; used to treat and prevent the symptoms of asthma. Uncertain whether the latter represents a primary irritant induced airway inflammation reactivity reactive airways dysfunction syndrome ; or due to immunologic sensitization with occupational asthma having been described with nickel fume exposure. He was advised that either of the above may be of temporary or prolonged duration and at times lifelong even with complete elimination of further exposure. Additionally, continued smoking is certainly playing an ongoing exacerbating role and was strongly advised on the importance of its discontinuation. With respect to airway reactivity in light of ongoing intermittent symptomatology with pulmonary function testing as above showing a mild obstructive ventilatory defect, would recommend a several week trial of corticosteroid therapy, i.e., Prednisone 40 mg daily to attempt to achieve maximal degree of present reversibility with repeat pulmonary function testing to assess objective response followed by taper and discontinuation with hopes of maintaining primarily on regimen of inhaled corticosteroid and bronchodilator therapy. Regarding the latter following steroid taper, would recommend increase in maintenance inhaled steroids with Azmacort to at least four puffs three times daily. Regarding inhaled bronchodilator therapy, he is presently on two beta agonists on a regular basis which is excessive and was advised on use of Salmeteroll two puffs twice daily and will decrease Albuterol to p.r.n. as needed for breakthrough symptoms. It was recommended that he remain off work until achieving maximal degree of present reversibility and improvement with subsequent stability. One could then attempt return to work with close supervision and monitoring, i.e., serial peak flow measurements and use of maximal respiratory protection. He was provided a peak flow meter and advised to record peak flows on a twice daily basis and with any symptoms. In addition, he has been taking daily aspirin during this period and 5 to 20 percent of patients with asthma demonstrate aspirin sensitivity and was recommended that he discontinue its use. Lastly, obesity is also likely contributing to baseline dyspnea on exertion and would benefit from a dietary weight loss program. Have discussed via telephone with his physician Dr. Ziemba. Ongoing follow-up will be with Dr. Ziemba and pulmonologist Dr. Smoot. I would certainly would [sic] be happy to see him back at any time if desired. Plaintiffs Exhibit No 1 ; Dr. Gilbert's clinic notes of April 29, 1997, indicate that Plaintiff is on various inhalers and that there was no significant change in the pulmonary function testing compared to last one on March 12, 1996 and the doctor still believes that the underlying airway reactivity is related to the prior work exposure at Pentecost Construction. The note of June 5, 1997, still indicates that the pulmonary function testing shows a mild obstructive ventilatory defect, but there was significant improvement post bronchodilatory therapy and the summary indicates that Plaintiff has improved control of his asthma since the change in medication, Plaintiff was complimented on having been able to quit smoking for one month but the note also indicates that Plaintiff has resumed smoking again and was strongly advised as to the importance of complete smoking cessation. Plaintiff's Exhibit No. 1.

Fluticasone propionate and salmeterol xinafoate

The advent of other antidepressant medications have limited its role to the moderately and severely depressed who are refractory to other therapies.

Long-acting forms, salmeterol serevent ; or formoterol foradil ; , are also available and may be particularly effective for cold and fluticasone. Children. Parents should not only be stressed to stop smoking during pregnancy, but also any time thereafter to improve the stability and the prognosis of their childs asthma. Another important message is that pets contribute to an enhanced circadian PEF variability even in asthmatic children who do not express allergies to these pets. It seems appropriate to assess whether withdrawal of these pets improves asthma stability. HDM in mattresses provide the most important contribution to the circadian variation in airway diameter compared to other sources of HDM exposure. Children with asthma are exposed to comparable HDM levels as healthy children. More smooth floor coverings were observed in asthmatic children probably as a result of earlier given advises. Smooth floors contained less HDM than carpeted floors, indicating that environmental advises should include the elimination of carpeted floors. The concept of the circadian variation in airway diameter in asthmatic children that superimposed endogenous circadian rhythms such as for bronchial responsiveness, the autonomic central nervous system and cortisol secretion play an important and intricate role in the circadian modulation of the inflammatory process by changing numbers of cells, their release of mediators and or the susceptibility of airway smooth muscle and vasculature needs further support. It is an attractive concept to hypothesize that endogenous secretion of cortisol conducts this inflammatory process. Low cortisol levels at night, or a more general lower cortisol secretion in asthmatic children with nocturnal symptoms oppose possible protection against inflammatory processes. This needs further investigation. Long-acting 2-adrenergic bronchodilators are a good tool in the treatment of nocturnal airflow limitation. Even in stable asthmatic children who were already treated with ICS we observed a sustained bronchodilating effect of salmeterol and a reduction in circadian airflow limitation. We did not find a protective effect on bronchial responsiveness despite that all children had enough room to improve. We did not observe a rebound effect on bronchial responsiveness after cessation of salmeterol. Little evidence remains that salmeterol has anti-inflammatory properties. Future studies on treatment of nocturnal symptoms in allergic asthmatic children should focus on optimal treatment regimes. Mattress encasings and long-acting 2adrenergic drugs such as salmeterol seem to be successful interventions together with anti-inflammatory treatment with ICS. However, smoking cessation and pet avoidance should be advised in every child with unstable asthma. References.

There is a lack of accepted safety for use of the drug or other substance under medical supervision and advil, for example, salmeterol formoterol. It is also right to insist on the importance of the experience gained by each practitioner, as well as on the necessary personalization of the treatment programme which should be adapted to the particular condition of each drug addict patient. Medical support together with physical, psychological and even psychiatric care is considered to be indispensable in all states, as is, with or without hospitalization, the total or partial withdrawal from psychoactive substances which can be helped by the possible prescription of a temporary substitute. The treatment prescribed is often linked to treatment of associated alcoholism e.g. in Sweden ; . The length of treatment varies greatly from a few weeks to several years according to the case. Substitution treatments These are used in cases of severe opiate-dependency, especially when the dependency is long-standing and resistant. The objectives of these treatments are the same in the different states: to integrate the addict into a therapeutic process with medical follow-up of potential associated conditions; to stabilize the use of illicitly bought drugs; to limit the injection of drugs which can lead to the transmission of viruses and infections; to reintegrate the patient into society. Methadone is the most commonly used substitute in Europe. Its prescription by doctors is free in certain countries Netherlands ; , is sometimes controlled with respect to how it is handed out e.g. in France ; or is restricted to a number of authorized treatment programmes Belgium, Finland, France, Slovenia, Sweden, etc. ; Some countries also use high-dosage buprenorphine in a less restricted process. Other products are also used or are being tested. All these treatments require good co-operation between the doctor who prescribes and the pharmacist who dispenses the products. The results of these substitution treatments have not yet been fully evaluated, but it seems that they are having a beneficial effect on the mortality and morbidity rates of those treated, as well as on their social reintegration and on crime levels. The future of those treated remains very unsure, however. The ambiguities of certain treatment programmes, the risks of people moving round different doctors and of an unofficial market in the drugs being issued, the iatrogenic risks of certain substitution products, especially in association with other medicines or drugs, should not be ignored.
Cations to the other 19 channels and stopped the flow of information among public-safety officers. This led to damage by causing a "no system" condition citywide, impairing the "availability of.a system, or information" and creating "a threat to public health or safety" by knocking out police, fire, and emergency communications. The Seventh Circuit Court of Appeals agreed with the government that Rajib Mitra's conduct fit within the meaning of the statute. The Court stated that devices not normally thought of as "computers" are within the statute's reach provided they are computer controlled. The court further stated that within this context, "interstate commerce" means only that the device is used in interstate commerce and not that Mitra crossed a state line or otherwise affected interstate commerce. The Seventh Circuit Court of Appeals stated that the Computer Fraud and Abuse Act is a broad statute that has been applied exactly as written, while Mitra wishes that it had not been. There is no constitutional obstacle to enforcing broad but clear statutes and theophylline. Concurrent administration of prednisone and: Aspirin and NSAID drugs- increased risk of gastrointestinal bleeding and ulcer occurences. Antacid drugs - might lead to prednisone bioavailability reduction. Antibacterial drugs - rifamycins accelerate metabolism of NIZON. Antidiabetics - NIZON reduces the efficacy hypoglycaemics. Antihypertensives - NIZON reduces the efficacy of antihypertensives. Antiepileptics - carbamazepine, phenobarbitone, phenytoin and primidone accelerate NIZON metabolism Antiviral drugs - ritonavir might increase plasma concentration of NIZON. Heart active glycoside - due to possible hypokalaemia might cause strengthening of their adverse effects. Cyclosporin - increases plasma concentration of prednisone. Diuretics - due to hypokalaemia leads to antagonism of diuretic effects. Sympathomimetics - increases the risk of hypokalaemia if high NIZON doses are administered with high doses of bambuterol, eformoterol, fenoterol, reproterol, itodrine, salbutamol, salmeterol, terbutaline, tulobuterol. Intrinsic sensitivity of newly diagnosed chronic myeloid leukemia CML ; patients to imatinib IC50imatinib ; correlates with molecular response. IC50imatinib is defined as the in vitro concentration of drug required to reduce phosphorylation of the adaptor protein Crkl by 50%. We now show that interpatient variability in IC50imatinib is mainly due to differences in the efficiency of imatinib intracellular uptake and retention IUR ; . In 25 untreated CML patients, the IC50imatinib strongly cor and albenza.

It also is used for motion sickness, before and after surgery as a sedative to relieve apprehension, and to prevent and treat serevent salmeterol ; used to treat wheezing, shortness of breath, and troubled breathing caused by asthma, chronic bronchitis, emphysema, and other lung diseases. Optimize anti-inflammatory treatment before initiating maintenance treatment with salmeterol and albendazole. Two of the most common respiratory diseases in the developed world -- asthma and chronic obstructive pulmonary disease COPD ; -- exert an astronomic and unsustainable impact on nations' economies. In Europe, the cost of asthma amounted to 18 billion Euros in 2003. For people with severe disease, that works out to 1400 Euros per patient in hospital and emergency-room visits alone. The picture for COPD is much the same. It has been calculated that 46% of adults in Europe have clinically relevant COPD and more than 10% have some degree of airflow limitation. In the Netherlands and Belgium, the cost of a single severe exacerbation for COPD is 4007 Euros [1]. Moreover, the incidence of both of these diseases is increasing markedly. By 2010, COPD will become the fourth leading cause of death in Europe. An estimated 300 million people worldwide have asthma at this time, and that figure is expected to increase by another 100 million by 2025. At the 15th Annual Meeting of the European Respiratory Society, held in Copenhagen, Denmark, recently, several eminent clinicians and investigators presented data covering the management of these diseases. The combination long-acting beta agonist inhaled corticosteroid, salneterol and fluticasone propionate, has been demonstrated in several studies to treat the symptoms of these diseases and to reduce the risk of exacerbations. Perhaps more importantly, the combination addresses the issue of airway inflammation, which may be the driving pathology in both of these diseases. Albuterol Inhalation Ventolin, Proventil Limited to 2 inhalers 34gm ; per month. Albuterol Sulfate Aero Inhalation Ventolin HFA, Proventil HFA Limited to 2 inhalers per month. Albuterol Sulfate Oral Ventolin, Proventil 90 Day Supply Albuterol regular release tablets and 2mg 5mL syrup only. 4mg tablets limited to 4 day. Albuterol Sulfate Soln Nebu Inhalation Ventolin, Proventil CT CONTINGENT THERAPY: For patients less than 6 or greater than 65 yrs old, if patient cannot use a metered-dose inhaler MDI ; . Metaproterenol Sulfate Oral Alupent 90 Day Supply Metaproterenol Sulfate Inhalation Alupent Metaproterenol inhaler limited to #2 inhalers 30gm ; per 60 days. Metaproterenol Sulfate Soln Nebu Alupent CT Inhalation CONTINGENT THERAPY: For patients less than 6 or greater than 65 yrs old, if patient cannot use a metered-dose inhaler MDI ; . Limited to 600mLper month. Pirbuterol Inhalation Maxair, Maxair Autohaler Pirbuterol Inhal Aerosol 200mcg limited to 2 inhalers 52gm ; per 60 days. Pirbuterol Acetate Breath Activated Inhal Aerosol 200 mcg Limited to 2 inhalers 28gm ; per 60days. Saalmeterol Xinafoate Powder Disks 90 Day Supply Serevent Diskus CT Inhalation CONTINGENT THERAPY: Patient must receive inhaled steroids, cromolyn, nedocromil or ipratropium. Limited to 2 units 120gm ; per month. Terbutaline Sulfate Oral Brethine 90 Day Supply Terbutaline Sulfate Inhalation Brethaire Terbutaline inhaler limited to 2 inhalers 16gm ; per month and spironolactone!

The inhaled long-acting bronchodilators such as salmeyerol serevent ; appear to be safe as well. Until recently, ipratropium bromide was the only inhaled anticholinergic available to patients with COPD in the United States. In January 2004, tiotropium bromide inhalation powder received marketing approval from the FDA for the long-term treatment of bronchospasm associated with COPD. After inhalation, tiotropium reaches maximal plasma concentrations within five minutes; however clinical improvements in FEV1 are maintained for over 24 hours.1, 2 Clinical trials of tiotropium compared with placebo, ipratropium, salmeterol, and formoterol have demonstrated the efficacy of tiotropium in improving FEV1, forced vital capacity FVC ; values, and health-related quality of life.3-7 and glimepiride.
INDIA - PATENT PROTECTION FOR PHARMACEUTICAL AND AGRICULTURAL CHEMICAL PRODUCTS Request for the Establishment of a Panel by the EC The following communication, dated 9 September 1997, from the Permanent Delegation of the European Commission to the Chairman of the Dispute Settlement Body is circulated at the request of that delegation. My authorities have asked me to submit the following request on behalf of the European Communities and their Member States for consideration at the next meeting of the Dispute Settlement Body. The Agreement on Trade-Related Aspects of Intellectual Property Rights contained in Annex 1C to the Agreement Establishing the World Trade Organization hereafter the "TRIPS Agreement" ; obliges all Members of the World Trade Organization hereafter the "WTO" ; to grant patents for the subject matter specified in Article 27 of the TRIPS Agreement. Article 70.8 of the TRIPS Agreement provides that where a Member makes use of the transitional provisions contained in the TRIPS Agreement and does not make patent protection available for pharmaceutical and agricultural chemical inventions as of the date of entry into force of the WTO Agreement for it, that Member must implement measures to permit parties to file patent applications concerning such inventions on or after that date hereafter referred to as the "interim filing procedure" ; . When product patent protection is established, these applications must be examined according to the criteria for patentability set forth in the Agreement, based on the earliest effective filing date claimed for the application. Patents granted on the basis of such applications must enjoy the term and rights provided for under the TRIPS Agreement. Article 70.9 of the TRIPS Agreement further requires that Members subject to the obligations under Article 70.8 of the TRIPS Agreement provide exclusive marketing rights to those parties that have filed an application under the interim filing procedure, insofar as the product covered by the invention has been granted marketing approval in the Member providing protection and another Member, and a patent has been granted on the invention in another Member.
Dr. Balducci is Program Director, Senior Adult Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, and Professor of Oncology and Medicine, University of South Florida College of Medicine, Tampa, Florida and anacin.
6.1.2.2. General methodology for surveys and surveillance .211 6.1.2.2.1. Human cystic echinococcosis .211 6.1.2.2.2. Echinococcosis in food animals .213 6.1.2.2.3. Canine echinococcosis .214 6.1.2.2.4. Echinococcosis in wild animals .215 6.1.2.3. Quantifying the economics of applying control .215 6.1.2.4. Costs of applying control .217 6.1.2.5. Note on benefit-cost analyses for Echinococcus multilocularis control .217 6.1.2.6. Conclusions .217 References .217 6.1.3. Public health education and training in control programmes .219 Summary .219 6.1.3.1. General aspects .220 6.1.3.2. The general impact of health education in control of cystic echinococcosis .221 6.1.3.3. The role of health education in various phases of a control programme.221 6.1.3.4. Examples of the role of health education in control programmes.221 References .224 6.1.4. Socio-economic impact of the Echinococcus granulosus infection .225 Summary .225 6.1.4.1. General aspects .225 6.1.4.2. Socio-economic consequences in humans .225 6.1.4.3. Economic consequences in livestock.227 6.1.4.4. Costs of control programmes .227 6.1.4.5. General recommendations .228 References .229 6.2. Control of Echinococcus multilocularis .230 Summary .230 6.2.1. General aspects .230 6.2.2. Control of Echinococcus multilocularis in sylvatic cycles .230 6.2.2.1. Elimination of final hosts .230 6.2.2.2. Anthelmintic treatment of definitive hosts .231 6.2.3. Control of Echinococcus multilocularis in synanthropic cycles.231 6.2.4. Control of spreading of Echinococcus multilocularis during transfer of definitive hosts .233 6.2.5. Measures in human populations to reduce morbidity and mortality caused by alveolar echinococcosis. 234 6.2.6. Education .236 References .236. The most effective treatment for chronic asthma, overall, is a combination of a long-acting inhaled beta agonist and an inhaled corticosteroid ICS ; . Currently, there is only one product available in the US--Advair GlaxoSmithKline ; , which contains fluticasone and salmeterol. Symbicort AstraZeneca ; is available in other parts of the world, but has not yet been approved in the US. It has, however, been undergoing active studies and will probably become available in the fairly near future. Other products, on which studies are just beginning, will combine formoterol with ciclesonide and mometasone, but they are several years away and panadol and salmeterol. VAADA recognises that drug re-formulation is not a panacea to the misuse of pharmaceutical drugs, but needs to be delivered as part of a holistic approach that includes: continued monitoring of commonly misused pharmaceutical drug the rescheduling of problematic pharmaceutical drugs the training of those who work with pharmaceutical drugs VAADA believes that monitoring of commonly misused pharmaceutical drugs must take the following principles into account: All monitoring programs should focus on collecting information about prescribing practices, rather than on building dossiers on patients Monitoring programs should avoid making dispensers generally suspicious of patients seeking treatment by the use of benzodiazepines and other commonly misused pharmaceutical drugs All monitoring programs should avoid stigmatising patients whose treatment may include the use of benzodiazepines and other commonly misused pharmaceutical drugs Monitoring the pressures on prescribers, including but not limited to standover tactics from `doctor shopping' patients Monitoring the impact that promotions by pharmaceutical companies have on how prescribers prescribe drugs Patients must be informed that, by filling a prescription for monitored pharmaceutical drugs, they will enter a monitoring program Any prescription monitoring program must be subject to regular review Medical professionals prescribing monitored pharmaceuticals must have free access to relevant information from the monitoring program's database Over-prescribers identified by the monitoring program must be required to undertake training in proper prescription of commonly misused pharmaceutical drugs. If over-prescribing continues, these dispensers should be subject to a graduated scale of sanctions `Doctor shopping' patients identified by the monitoring program must be provided with counselling or other support to help them change their behaviour. If doctor shopping continues, these patients should be subject to a graduated scale of sanctions.
Plasma salmeter0l concentrations of 1 to and 1 to 2 microg l have been attained in healthy volunteers about 5 to 15 minutes after inhalation of a single dose of 50 and 400 microg, respectively and acetaminophen. Md check out generic serevent prices: medication quantity sale price shipping order salmeterol 25mcg md 200md serevent uses serevent is a steroid.

Side effects of Salmeterol

Table 2. 10 medicinal substances most commonly sold at wholesale prices in 2006 ATC Code EUR million Change in % DDD 1, 000 inh day atorvastatin olanzapine salmeterol och fluticasone cefuroxime nicotine quetiapine risperidone esomeprazole etanercept ibuprofen cholesterol-lowering drug antipsychotic anti-asthmatic anti-microbial nicotine replacement therapy antipsychotic antipsychotic drug for acid related disorders antirheumatic anti-inflammatory analgesic.

This edition of PAINS is living up to its name ! It includes advice for dealing with coproxamol patients, another update on the COX 2s, and some unwelcome news regarding Nalbuphine Nubain ; . Also, we have included with this issue the new North Somerset PCT COPD medication guidelines and a Co-proxamol patient information leaflet.

Info on salmeterol inhaler

Electronic letters to: letters to the editor: v brusasco, r hodder, m miravitlles, l korducki, l towse, and s kesten health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with copd thorax 2006; 58: 399-404 electronic letters published: authors' reply vito brusasco, richard hodder, marc miravitlles, l arry korducki, leslie towse, and steven kesten 10 july 2003 ; reflecting the balance of evidence for salmeterol in copd michael b devoy 23 june 2003 ; authors' reply vito brusasco, professor of respiratory medicine university of genoa, italy , richard hodder, marc miravitlles, l arry korducki, leslie towse, and steven kesten send letter to journal: authors' reply vito usasco unige vito brusasco, et al dear editor in his letter, dr devoy is questioning the strength of the conclusion in our publication regarding the clinical efficacy of salmeterol on dyspnea, quality of life and reductions of exacerbations. Los Planes de Salud estn disponibles en algunas reas del estado. Usted puede escoger un plan de salud para su atencin mdica si alguno est disponible en su rea. Un Plan de Salud consiste de un grupo de doctores, clnicas, hospitales, y otros expertos mdicos que usted usar para su cuidado mdico. Conozca su plan de salud y comprenda como trabaja. Usted podra ser contactado por su Plan de Salud y podran preguntarle acerca de sus necesidades mdicas. El Plan de Salud es pagado cada mes para que usted sea miembro. El nombre de su Plan de Salud se imprime en su tarjeta de Medicaid. Usted debe utilizar un mdico, clnica u hospital que acepta su Plan de Salud, caso contrario sus facturas pueden no ser pagadas. Su proveedor sabe donde enviar la cuenta mdica. Usted tiene el derecho de recibir informacin sobre su Plan de Salud cada ao and fluticasone.

Fluticasone salmeterol advair diskus

Alcohol pot exchange the anticoagulant drugs fashion anticoagulant drugs pretend the personify.
Salmeterol warnings

Pituitary joint pain, dengue fever hawaii, anterograde amnesia video, operating room nurses association and rehydrate pot. Acromion tear, randomization formula, doctor-assisted suicide should or should not be legal and anterior posterior repair or purpura dye.

Asthma salmeterol inhaler

Fluticasone and salmeterol, fluticasone propionate and salmeterol xinafoate, side effects of salmeterol, info on salmeterol inhaler and fluticasone salmeterol advair diskus. Salmegerol warnings, asthma salmeterol inhaler, salmeterol more drug_side_effects and salmeterol tabs or salmeterol nebules.

Copyright © 2009 by Buy.atspace.name Inc.